Archive for the 'Cystic Fibrosis' Category
Scorpion Peptide May Be Key To Secretory Diseases
Researchers have discovered a peptide in scorpion venom that may hold the key to understanding and controlling cystic fibrosis and other secretory diseases.In the December 28 issue of the Journal of Biological Chemistry, an universal team of researchers describes how that novel peptide, called GaTx1…
Drug Fights Cystic Fibrosis
An experimental drug that has proven effective in treating muscular dystrophy plus works for cystic fibrosis, according to researchers at the University of Alabama at Birmingham (UAB).The new study is the latest on a compound called PTC124, which helps to “rescue” faulty proteins that lead to illnes…
PTC Therapeutics Announces Publication Of Preclinical goods In PNAS
PTC Therapeutics, Inc. nowadays announced the publication of new preclinical documents in the February 12, 2008 edition of the Proceedings of the National Academy of Sciences (PNAS) which show that PTC124, a novel drug designed to bypass nonsense mutations, was active in a preclinical model of cysti…
Rural Equal To City In Cystic Fibrosis Treatment, Australia
Outreach services for cystic fibrosis (CF) patients in remote areas are as effective as the treatment and management centres in metropolitan areas, according to a study published in the latest Medical Journal of Australia.Original post by Dentistry News From Medical News Today
Cystic Fibrosis Foundation Reports Upward Trend For Key Health Outcomes
The Cystic Fibrosis Foundation reported that key indicators of health for citizens with cystic fibrosis — including lung function and nutritional status — are rising nationwide across its accredited care center network. In fact, the outlook for citizens with CF continues to improve steadily e…
EPIX Pharmaceuticals Achieves 1.25 Million Dollars Milestone In Collaboration With Cystic Fibrosis Foundation Therapeutics
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced that it has received a $1.25 million milestone payment from Cystic Fibro…
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects Triolex (He3286) As A Oral Anti-Inflammatory Drug Candidate
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the leader in the development of a new lesson of small molecule compounds based on endogenous steroid hormones, announced that Cystic Fibrosis Foundation Therapeutics, Inc, (CFFT), the non-profit drug discovery and development affiliate of the Cystic …
Cystic Fibrosis: License Agreement Boosts Development Of Therapy Against Lung Infections
An exclusive license for the development and commercialisation of a drug delivery system for lung infections in Cystic Fibrosis patients was signed. As part of the agreement, aRigen Pharmaceuticals Inc., Japan transferred relevant rights to Axentis Pharma AG of Switzerland. The EMEA has …
From Cystic Fibrosis Registry To Quality Management
Since 1995, the German Cystic Fibrosis Quality Assessment project has been collecting demographic goods and outcome parameters from 6,835 patients treated by 93 centres, in order to improve healthcare for cystic fibrosis (CF) patients. Coverage of 83% of patients has been achieved in Germany. [click…
Clues To Gastrointestinal Disease And Cystic Fibrosis Gene Dysfunction Revealed By Study
A new study by researchers at Hasbro Children’s Hospital, the pediatric division of Rhode Island Hospital, and Mount Sinai Hospital, New York, offers new insight into the role that the cystic fibrosis gene plays in the development of gastrointestinal disease.The cystic fibrosis transmembrane conduct…
Copernicus Receives Milestone Payment From CFFT To Further Development Of Its Non-Viral Gene Therapy For Cystic Fibrosis
Copernicus Therapeutics, Inc. announced that it received a milestone payment from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit affiliate of the Cystic Fibrosis Foundation. that milestone payment is part of a research, development, and commercialization agreement amoung CFFT and…













